Tranexamic acid is safe to use following mild-to-moderate traumatic brain injury

Rob Cook; Johnny Lyon-Maris; Rosie Martin; NIHR Dissemination Centre

doi:10.1136/bmj.m514

Tranexamic acid is safe to use following mild-to-moderate traumatic brain injury

BMJ. 2020 Mar 11:368:m514. doi: 10.1136/bmj.m514.

Authors

Rob Cook¹, Johnny Lyon-Maris², Rosie Martin¹; NIHR Dissemination Centre

Affiliations

¹ Bazian, Economist Intelligence Unit healthcare, London, UK.
² Wessex Institute, University of Southampton, Southampton, UK.

PMID: 32161036
DOI: 10.1136/bmj.m514

Abstract

The studyThe CRASH-3 Trial Collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019;394:1713-23.This trial was funded by NIHR Health Technology Assessment Programme (project number 14/190/01), JP Moulton Charitable Trust, Department of Health and Social Care, Department for International Development, Global Challenges Research Fund, Medical Research Council, and the Wellcome Trust (Joint Global Health Trials scheme).To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000870/tranexamic-acid-following-mild-to-moderate-traumatic-brain-injury-is-safe-and-reduces-deaths.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Publication types

Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Antifibrinolytic Agents*
Brain Injuries, Traumatic*
Humans
Technology Assessment, Biomedical
Tranexamic Acid
Vascular Diseases*

Substances

Antifibrinolytic Agents
Tranexamic Acid

Abstract

Publication types

MeSH terms

Substances

Grants and funding